Relay Therapeutics (RLAY) Return on Capital Employed (2020 - 2026)

Relay Therapeutics (RLAY) has 7 years of Return on Capital Employed data on file, last reported at 47.0% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 47.0%, down 103.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 47.0% (down 103.0% YoY), and the FY2025 annual result was 42.0%, up 416.0% from the prior year.
• Return on Capital Employed climbed to 47.0% in Q1 2026 per RLAY's latest filing, from 48.82% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 27.96% in Q4 2022 and troughed at 49.05% in Q3 2025.
• A 5-year average of 41.67% and a median of 44.13% in 2023 frame the typical range for Return on Capital Employed.
• On a YoY basis, Return on Capital Employed climbed as much as 1675 bps in 2022 and fell as far as 3175 bps in 2022.
• A 5-year view of Return on Capital Employed shows it stood at 27.96% in 2022, then slumped by 58 bps to 44.13% in 2023, then advanced by 1 bps to 43.82% in 2024, then dropped by 11 bps to 48.82% in 2025, then climbed by 4 bps to 47.0% in 2026.
• Business Quant data shows RLAY's Return on Capital Employed at 47.0% in Q1 2026, 48.82% in Q4 2025, and 49.05% in Q3 2025.